Cellectis S.A. (CLLS)
NASDAQ: CLLS · Real-Time Price · USD
1.640
+0.050 (3.14%)
Dec 20, 2024, 4:00 PM EST - Market closed
Cellectis Employees
As of December 31, 2023, Cellectis had 221 total employees, including 216 full-time and 5 part-time employees. The number of employees decreased by 16 or -6.75% compared to the previous year.
Employees
221
Change (1Y)
-16
Growth (1Y)
-6.75%
Revenue / Employee
$163,086
Profits / Employee
-$382,253
Market Cap
155.56M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
The Joint | 794 |
Adaptimmune Therapeutics | 449 |
Sutro Biopharma | 302 |
Seres Therapeutics | 233 |
Pro-Dex | 148 |
Biomea Fusion | 103 |
Nanobiotix | 102 |
Corbus Pharmaceuticals Holdings | 19 |
CLLS News
- 9 days ago - Cellectis: Poised To Start Answering Questions In 2025 - Seeking Alpha
- 11 days ago - Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB) - GlobeNewsWire
- 6 weeks ago - Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting - GlobeNewsWire
- 6 weeks ago - Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Cellectis Provides Business Updates and Financial Results for Third Quarter 2024 - GlobeNewsWire
- 7 weeks ago - Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024 - GlobeNewsWire
- 2 months ago - Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress - GlobeNewsWire
- 3 months ago - Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety - GlobeNewsWire